March 13, 2018 / 7:47 AM / 4 months ago

BRIEF-‍Avillion Signs Co-Development agreement With Astrazeneca's unit Pearl Therapeutics

March 13 (Reuters) - Avillion:

* ‍AVILLION SAYS SIGNED CO-DEVELOPMENT AGREEMENT WITH PEARL THERAPEUTICS INC. (PART OF ASTRAZENECA) TO CONDUCT CLINICAL DEVELOPMENT OF PT027 IN ASTHMA​

* ‍AVILLION SAYS WILL BE RESPONSIBLE FOR DEVELOPING PT027 THROUGH A CLINICAL DEVELOPMENT PROGRAMME, WILL FINANCE PROGRAMME THROUGH TO REGULATORY APPROVAL.​

* ‍AVILLION SAYS NO FINANCIAL TERMS ARE DISCLOSED.​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below